| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/25/2011 | CA2338186C Tumor necrosis factor-gamma |
| 01/25/2011 | CA2337857C Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate |
| 01/25/2011 | CA2333833C Specific binding molecules for scintigraphy,conjugates containing them and therapeutic method for treatment of angiogenesis |
| 01/25/2011 | CA2303509C Modified timp |
| 01/25/2011 | CA2295540C Improved anti-ige antibodies and method of improving polypeptides |
| 01/25/2011 | CA2174098C Method of inducing and maintaining neuronal cells |
| 01/22/2011 | CA2710693A1 Pharmaceutical compositions |
| 01/20/2011 | WO2011009119A2 Compositions and methods for diagnosing and treating fibrotic disorders |
| 01/20/2011 | WO2011009042A2 Antigen compositions and methods of inhibiting campylobacter jejuni bacterial infection and uses of the antigen compositions |
| 01/20/2011 | WO2011008996A2 Peptides whose uptake in cells is controllable |
| 01/20/2011 | WO2011008956A2 Mammalian genes involved in infection |
| 01/20/2011 | WO2011008885A1 Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
| 01/20/2011 | WO2011008823A2 Peptide-mediated non-covalent delivery of active agents across the blood brain barrier |
| 01/20/2011 | WO2011008713A1 Process and system for obtaining botulinum neurotoxin |
| 01/20/2011 | WO2011008548A1 Vaccines and compositions against streptococcus pneumoniae |
| 01/20/2011 | WO2011008495A2 Arginase formulations and methods |
| 01/20/2011 | WO2011008274A2 Reduced volume formulation of glatiramer acetate and methods of administration |
| 01/20/2011 | WO2011008260A2 Bifunctional stapled polypeptides and uses thereof |
| 01/20/2011 | WO2011007961A2 Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes |
| 01/20/2011 | WO2011007885A1 Proteoglycan-containing material |
| 01/20/2011 | WO2011007792A1 Enzyme composition |
| 01/20/2011 | WO2011007747A1 Sugar chain-added ailim extracellular domain and method for producing same |
| 01/20/2011 | WO2011007612A1 Anti-inflammatory agent for oral application, and anti-inflammatory peptide for oral application |
| 01/20/2011 | WO2011007350A2 Immunomodulatory agents and a tissue-targeted delivery system thereof for the treatment of immune-related disorders |
| 01/20/2011 | WO2011007337A2 Cosmetic use of lacritin-type polypeptides |
| 01/20/2011 | WO2011006994A1 Hdl comprising a therapeutic agent and use in therapy |
| 01/20/2011 | WO2011006497A1 Acylated glucagon analogues |
| 01/20/2011 | WO2011006226A1 Proteins, protease inhibiting peptides and derivatives thereof, medicinal, nutraceutical and cosmeceutical compositions based on these compounds, and uses thereof for preparing formulations for the treatment and prevention of cancer or diseases involving protease inhibition |
| 01/20/2011 | WO2010135541A3 Variants of c-type natriuretic peptide |
| 01/20/2011 | WO2010135277A3 Cyclic-glur6 analogs, methods of treatment and use |
| 01/20/2011 | WO2010134827A9 Extended acting oxygen generating composition for treating microbial infections |
| 01/20/2011 | WO2010125148A3 Methods for treating ocular conditions |
| 01/20/2011 | WO2010118404A3 Methods for creating or identifying compounds that bind tumor necrosis factor alpha |
| 01/20/2011 | WO2010107874A3 Methods for affecting body composition using amylin agonists |
| 01/20/2011 | WO2010107658A3 Methods and compositions for bi-specific targeting of cd19/cd22 |
| 01/20/2011 | WO2010038228A3 Method and system for emitting light |
| 01/20/2011 | WO2010002283A9 New insulin analogues of prolonged activity |
| 01/20/2011 | WO2009004595A3 Enhancement of the efficacy of therapeutic proteins |
| 01/20/2011 | WO2006097924A8 Cyclic phosphates as plant growth regulators |
| 01/20/2011 | WO2003034984A9 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| 01/20/2011 | WO2003024409A3 Q4n2neg2 enhances cftr activity |
| 01/20/2011 | US20110016538 Susceptibility locus for schizophrenia |
| 01/20/2011 | US20110015586 Application of polymeric materials to screens to facilitate hemostasis and wound healing |
| 01/20/2011 | US20110015376 Papilloma Virus-Like Particles, Fusion Proteins as Well as Processes for Their Production |
| 01/20/2011 | US20110015371 Inhibitors of interleukin-1 beta converting enzyme |
| 01/20/2011 | US20110015139 Histidine related compounds for identifying and blocking amyloid beta ion channels |
| 01/20/2011 | US20110015138 Inhibition of inflammation using antagonists of muc1 |
| 01/20/2011 | US20110015137 Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity |
| 01/20/2011 | US20110015136 humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration |
| 01/20/2011 | US20110015135 Antitumoral Treatments |
| 01/20/2011 | US20110015134 Method of treatment for early stage cancer |
| 01/20/2011 | US20110015133 Pax2 and pax8 as tumour targets for immunologic and molecular treatment strategies |
| 01/20/2011 | US20110015132 Synergistic 5'-methylthioadenosine combinations |
| 01/20/2011 | US20110015131 Methods for preventing and treating alzheimer's disease (ad) |
| 01/20/2011 | US20110015130 Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof |
| 01/20/2011 | US20110015129 New paediatric indications for direct thrombin inhibitors |
| 01/20/2011 | US20110015128 Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
| 01/20/2011 | US20110015127 Targeting complement factor h for treatment of diseases |
| 01/20/2011 | US20110015126 Compositions and Methods For Inducing Apoptosis In Tumor Cells |
| 01/20/2011 | US20110015125 Adhesives and methods of applying the same |
| 01/20/2011 | US20110015124 Leptin agonist and methods of use |
| 01/20/2011 | US20110015123 Modulation of GLUT4 Gene Promoter activity BY AHNAK |
| 01/20/2011 | US20110015122 Hepatitis b virus-binding polypeptides and methods of use thereof |
| 01/20/2011 | US20110015121 Cyclic compound and salt thereof |
| 01/20/2011 | US20110015120 Pharmaceutical and cosmetic compositions including lactoferrin, ciclopirox, etidronic acid |
| 01/20/2011 | US20110015119 Novel semi-synthetic glycopeptides as antibacterial agents |
| 01/20/2011 | US20110015118 C-Terminal Ifapsoriasin Fragments as Antimicrobial Peptides, the Production Thereof and Use Thereof |
| 01/20/2011 | US20110015117 Methods for increasing absorption of peptides, peptidomimetics and other gastrointestinal transport protein substrates |
| 01/20/2011 | US20110015116 Method for treating muscular dystrophy |
| 01/20/2011 | US20110014675 Poly zinc finger proteins with improved linkers |
| 01/20/2011 | US20110014635 Marker peptide for alzheimer's disease |
| 01/20/2011 | US20110014628 Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy |
| 01/20/2011 | US20110014297 Multimodal therapeutic hybrid particle complex and system |
| 01/20/2011 | US20110014296 Drug Delivery Nanodevice, its Preparation Method and Uses Thereof |
| 01/20/2011 | US20110014290 System and method for facilitating hemostasis with an absorbable sponge |
| 01/20/2011 | US20110014289 Reticulated Elastomeric Matrices, Their Manufacture and Use in Implantable Devices |
| 01/20/2011 | US20110014281 Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| 01/20/2011 | US20110014279 Bioactive complex compositions and methods of use thereof |
| 01/20/2011 | US20110014277 Smoking Cessation With Body Weight Maintenance And Nutritional Supplement |
| 01/20/2011 | US20110014270 Prevention and treatment of ischemia-reperfusion injury and related conditions |
| 01/20/2011 | US20110014264 Medical Devices Having Nanostructured Regions For Controlled Tissue Biocompatibility And Drug Delivery |
| 01/20/2011 | US20110014247 Methods and compositions for oral administration of proteins |
| 01/20/2011 | US20110014229 Chimeric flavivirus vectors |
| 01/20/2011 | US20110014223 Multimeric proteins able to induce an antibody response against the beta-amyloid and use thereof |
| 01/20/2011 | US20110014218 Ixodes scapularis salivary proteins and methods of use for modulation of the alternative complement pathway |
| 01/20/2011 | US20110014214 Diagnostic and Therapeutic Utility of Tribbles-2 in Human Cancers |
| 01/20/2011 | US20110014212 Certain Chemical Entities, Compositions and Methods |
| 01/20/2011 | US20110014210 Chlamydia vaccine |
| 01/20/2011 | US20110014209 Recombinant hcv e2 glycoprotein |
| 01/20/2011 | US20110014204 Cancer Chemoprevention Strategy Based on Loss of Imprinting of IGF2 |
| 01/20/2011 | US20110014197 Methods of treating pre-eclampsia or eclampsia |
| 01/20/2011 | US20110014196 Drug Transfer into Living Cells |
| 01/20/2011 | US20110014195 Use of therapeutic peptides for the treatment and prevention of cancer |
| 01/20/2011 | US20110014190 Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
| 01/20/2011 | US20110014188 TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease |
| 01/20/2011 | US20110014185 Methods involving graf polypeptides |
| 01/20/2011 | US20110014182 Antigen binding proteins |
| 01/20/2011 | US20110014180 Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue |
| 01/20/2011 | US20110014179 Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich) in a selected subpopulation of ich patients |
| 01/20/2011 | US20110014178 Antimicrobial Composition and Method for Use |